HCAT vs. CDLX, VNET, EB, JG, HSTM, IAS, BMBL, GDS, HUYA, and TBLA
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Cardlytics (CDLX), VNET Group (VNET), Eventbrite (EB), Aurora Mobile (JG), HealthStream (HSTM), Integral Ad Science (IAS), Bumble (BMBL), GDS (GDS), HUYA (HUYA), and Taboola.com (TBLA). These companies are all part of the "computer programming, data processing, & other computer related" industry.
Cardlytics (NASDAQ:CDLX) and Health Catalyst (NASDAQ:HCAT) are both small-cap business services companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership.
Health Catalyst has lower revenue, but higher earnings than Cardlytics. Health Catalyst is trading at a lower price-to-earnings ratio than Cardlytics, indicating that it is currently the more affordable of the two stocks.
Cardlytics presently has a consensus price target of $12.75, suggesting a potential upside of 45.55%. Health Catalyst has a consensus price target of $12.18, suggesting a potential upside of 83.74%. Given Cardlytics' higher possible upside, analysts clearly believe Health Catalyst is more favorable than Cardlytics.
In the previous week, Health Catalyst had 2 more articles in the media than Cardlytics. MarketBeat recorded 4 mentions for Health Catalyst and 2 mentions for Cardlytics. Cardlytics' average media sentiment score of 0.94 beat Health Catalyst's score of 0.43 indicating that Health Catalyst is being referred to more favorably in the news media.
Cardlytics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 1.32, meaning that its stock price is 32% more volatile than the S&P 500.
68.1% of Cardlytics shares are held by institutional investors. Comparatively, 85.0% of Health Catalyst shares are held by institutional investors. 4.4% of Cardlytics shares are held by company insiders. Comparatively, 2.7% of Health Catalyst shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Cardlytics received 73 more outperform votes than Health Catalyst when rated by MarketBeat users. However, 67.74% of users gave Health Catalyst an outperform vote while only 58.20% of users gave Cardlytics an outperform vote.
Health Catalyst has a net margin of -35.56% compared to Health Catalyst's net margin of -55.23%. Cardlytics' return on equity of -11.86% beat Health Catalyst's return on equity.
Summary
Health Catalyst beats Cardlytics on 11 of the 18 factors compared between the two stocks.
Get Health Catalyst News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCAT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Health Catalyst Competitors List
Related Companies and Tools
